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The treatment of advanced and poor-risk multiple
myeloma (MM) is still a major challenge and no therapy has
proven to be curative or effective long term. Although allo-
geneic HCT has curative potential, the outcomes remain poor
due to high treatment-related mortality (TRM) after full-
intensity conditioning, high relapse rate after reduced-
intensity regimens and possibly other disease-speciﬁc issues.
Under an IRB approved protocol at the University of Michi-
gan, we enrolled 22 patients onto a phase 2 trial exploring
the feasibility and efﬁcacy of an intermediate-intensity
conditioning with ﬂudarabine and busulfan x 4 (FluBu4)
[ﬂudarabine 40mg/m2/day and busulfan 3.2mg/kg/day IV x 4
days], followed by allogeneic HCT between 2008 and 2011.
Eligible patients included those with high-risk MM, deﬁned
as unfavorable cytogenetics [t(4;14), t(14;16), t(14;20), -13,
-17p] or early relapse post autologous HCT. The median age
was 54 years (range, 45-70 years). The majority (64%) had
prior autologous HCT. The median HCT-speciﬁc comorbidity
index (HCT-CI) score was 3 (0-6), with 46% having a Karnof-
sky performance score 80%. Donor types [total (match+
mismatch)] were 12 (10+2) related and 10 (7+3) unrelated.
GVHD prophylaxis was tacrolimus / methotrexate in 20
(91%). Disease status was complete response in 3 (14%), very
good partial response in 6 (27%), partial response in 12 (54%)
and stable disease in 1 (4.5%).
All 22 patients tolerated the conditioning regimen
without early toxic deaths or graft failure. Common regimen-
related toxicities (RRT) include mucositis (19, 86%) and mild
transient liver function abnormality (13, 59%). Grade 3-4
mucositis occurred in 9 patients (41%). Cumulative incidence
of grade II-IV acute GVHD was 48% (95% conﬁdence interval
[CI]; 29-72%), grade III-IV acute GVHD was 23% (95%CI; 10-
47%) and chronic GVHD at 1 year was 55% (95%CI; 34-78%).
Cumulative incidences of relapse at 1 and 3 years were both
29% (95% CI; both 14-55%) and TRM at 100 days, 1 and 3 years
were 9% (95%CI; 2-33%), 19% (95%CI; 7-44%) and 33% (95%CI;
17-59%), respectively. Of note, TRM was due to idiopathic
pneumonia syndrome in 2 (9%) and cirrhosis in 1 (4.5%). All
had a marginal HCT-CI score of 3, 4 and 6 pre-HCT. With
a median follow-up of 9.5 months (range, 2-38 months), the
1- and 3-year overall survival was 61% (95%CI; 43-87%) and
33% (95%CI; 17-64%), and the 1- and 3-year progression free
survival was 40%(95%CI; 23-67%) and 15% (95%CI; 5-42%)
[Figure 1]. In summary, allogeneic HCT using an interme-
diate-intensity FluBu4 conditioning for high-risk MM is safe
and feasible, with similar TRM, compared with the published
reduced-intensity experience. Although disease recurrence
continues to be a major issue, this regimen is a promising
platform to combine the beneﬁt of a graft-versus-myeloma
effect with new maintenance strategies, in order tomaximize the chance of a long-term remission in poor-risk
MM patients.
Figure 1.
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Due in part to a potential graft versus myeloma effect,
allogeneic stem cell transplantation is a potentially curative
treatment modality in patients with multiple myeloma
(MM). Initial attempts have been hampered by the high
transplant-related mortality in this setting. With a reduction
of toxicity, allogeneic transplant approaches with reduced-
intensity conditioning (RIC) have been utilized, although
they are subject to continued disease progression and
relapse following transplantation. We analyze here the
experience of allografting four patients with MM in a single
institution, along a 16-years period in which a total of 152
individuals where allografted, using a reduced-intensity
conditioning regimen; three of the patients have had
previous autografts. All patients engrafted successfully and
a graft versus-myeloma effect was shown in all of them. One
patient relapsed in the face of graft versus host disease
(GVHD). Three patients have died (two as a result of GVHD)
and one is alive with a limited form of chronic GVHD. The
graft versus myeloma effect can be induced by means of
allogeneic transplantation but the morbidity and mortality
associated with the procedure leads into a relatively small
proportion of MM patients being cured.
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Relapsed or primary refractory Hodgkin's (HL) and Non
Hodgkin's lymphomas (NHL) are rescued, with the potential
of cure with autologous hematopoietic cell transplantation
(AHCT). The conditioning regimens used are considered
equal and none has demonstrated any superiority. During
the last 2 years, primarily due to Carmustine (BCNU)
unavailability, a new alternative conditioning regimen was
